我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1964
暂无试验阶段数据
尚未招募
100.0%
暂无批准数据
- Bempedoic acid has received a Class I, Level A recommendation in the 2025 ESC/EAS Guidelines for Management of Dyslipidaemias, marking the strongest endorsement for a non-statin therapy. - The guidelines recommend bempedoic acid for patients unable to take statin therapy to lower LDL-C levels and reduce cardiovascular events, with additional consideration for high-risk patients on maximally tolerated statin therapy. - The updated European guidelines emphasize earlier, aggressive combination therapy approaches, supporting Esperion's development of oral triple combination lipid-lowering therapies in the U.S. - Esperion's CEO highlighted that this European recognition validates bempedoic acid's clinical benefit and is expected to inform upcoming U.S. cholesterol treatment guidelines.